A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
A phase 3 trial of Tucidinostat, Sintilimab, Bevacizumab in colorectal cancer, run by Chipscreen Biosciences, Ltd., now recruiting.
Overview
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients is a phase 3 interventional study registered as NCT06497985 by Chipscreen Biosciences, Ltd., with 430 participants planned, started 2024-12-06 and due to reach its primary completion in 2028-05-31. Interventions recorded: Tucidinostat, Sintilimab, Bevacizumab, Fruquintinib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- CompanyHUYABIO International
- TrialA Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer
Shares Sintilimab, Colorectal cancer.
- TrialA Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Shares Fruquintinib, Colorectal cancer.
- TrialStudy of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Shares Fruquintinib, Sintilimab.
- TrialA Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Shares Fruquintinib, Colorectal cancer.
- TrialStudy of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Shares Sintilimab, Bevacizumab.
- TrialA Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Shares Fruquintinib, Bevacizumab.
- TrialStudy of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Shares Fruquintinib, Colorectal cancer.